La chaîne d'options affiche les données clés des options sur actions de Bioventus à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Bioventus..

Bioventus (NASDAQ:BVS) Stock, Chaîne d'Options

Bioventus

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Bioventus Inc

BRAVURA SOLUTIONS LTD by Bravura Solutions Ltd.

Bravura Solutions Ltd

Scotiabank analyst Meny Grauman assumes Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform rating and announces Price Target of C$188.

News

Price Target

Initiation

Analyst Ratings

TSX:RY

Scotiabank Assumes Royal Bank of Canada at Sector Outperform, Announces Price Target of C$188

HC Wainwright &amp; Co. analyst Kevin Dede maintains DeFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) with a Buy and raises the price target from $4.5 to $5.5.

DEFT

HC Wainwright & Co. Maintains Buy on DeFi Technologies, Raises Price Target to $5.5

The study also met a secondary endpoint of overall survival (OS) in patients whose tumors express PD-L1. The study is evaluating KEYTRUDA&#xAE; (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. The trial is continuing and OS for the full study population will be evaluated at a future analysis.&nbsp;

Biotech

Large Cap

Health Care

General

Merck's Keytruda Phase 3 KEYNOTE-B96 Trial (Also Known As ENGOT-ov65) Met Its Primary Endpoint Of Progression-free Survival For Patients With Platinum-resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 And In All Comers

Scotiabank analyst Meny Grauman assumes Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) with a Sector Outperform rating and announces Price Target of C$98.

TSX:CM

Scotiabank Assumes Canadian Imperial Bank at Sector Outperform, Announces Price Target of C$98

ITT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) will host its 2025 Capital Markets Day today beginning at 1 p.m. ET in New York. Chief Executive Officer and President Luca Savi, Chief Financial Officer Emmanuel Caprais and members of ITT's extended leadership team will deliver a series of presentations covering the company's differentiation through execution, innovation and M&amp;A.
In connection with its Capital Markets Day, the company also announced new 2030 long-term financial targets. ITT expects to deliver the following financial results, all compared to actual results for the year ended Dec. 31, 2024:
<ul>
<li>More than 5% average annual organic revenue growth and approximately 10% total including expected contributions from acquisitions</li>
<li>~23% adjusted operating margin on a consolidated basis, an expansion of more than 500 basis points versus 2024</li>
<li>More than $11 of adjusted earnings per share (EPS) from existing businesses</li>
<li>Additionally, ITT expects to deploy between $500-700 million per year to accretive acquisitions which the company estimates would contribute an additional $0.75 to $1.00 of EPS toward more than $12 in total by 2030</li>
<li>14% to 15% free cash flow margin</li>
</ul>

ITT Outlines 2030 Long-Term Growth Targets: ITT Forecasts 10% Revenue Growth, 23% Adj. Opt. Margin, $12+ EPS Target By 2030

HC Wainwright &amp; Co. analyst Mike Colonnese maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and lowers the price target from $22 to $21.

IREN

HC Wainwright & Co. Maintains Buy on IREN, Lowers Price Target to $21

On Wednesday, May 14, U.S. markets closed mixed. The S&amp;P 500 closed slightly higher after a quiet session, with investors awaiting economic data following gains earlier in the week tied to easing inflation and a U.S.-China tariff pause.
Tech stocks rose on AI deals in the Middle East, while trade uncertainty and Fed signals kept markets cautious. The Dow slipped, and the Nasdaq advanced.
In economic data, U.S. mortgage applications rose slightly in the week ending May 9, up 1.1% from the previous week, easing after an 11% jump the week before.
Most S&amp;P 500 sectors fell Wednesday, led by losses in health care, materials, and real estate, while tech and communication stocks gained.
The Dow Jones Industrial Average declined 0.21% to 42,051.06, the S&amp;P 500 gained 0.10% to 5,892.58, and the Nasdaq surged 0.71% to 19,146.81.
Asia Markets Today
<ul class="wp-block-list">
<li>On Thursday, Japan's Nikkei 225 closed 0.88% lower at 37,793.00, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.</li>
<li>Australia's S&amp;P/ASX 200 gained 0.22%, ending the session at 8,297.50, led by gains in the IT, Financials, and Consumer Discretionary sectors.</li>
<li>India's Nifty 50 was up 1.52% at 25,044.25, and Nifty 500 rose 1.24% to 22,777.70.</li>
<li>China's Shanghai Composite declined 0.68% to 3,380.82, and Shanghai Shenzhen CSI 300 was down 0.91% at 3,907.20.</li>
<li>Hong Kong's Hang Seng closed the session 0.79% lower at 23,453.16.</li>
</ul>
Eurozone at 06:00 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.49%.</li>
<li>Germany's DAX index declined 0.10%.</li>
<li>France's CAC 40 fell 0.22%.</li>
<li>The U.K.'s FTSE 100 index traded higher by 0.08%.</li>
</ul>
Commodities at 06:00 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading lower by 3.71% at $60.81/bbl, and Brent was down 3.50% at $63.81/bbl.</li>
<li>Oil prices plunged nearly 4% on hopes of a U.S.-Iran nuclear deal that could boost supply, while global stocks paused after a rally driven by trade truce optimism and Middle East deals.</li>
<li>Natural Gas declined 0.23% to $3.486.</li>
<li>Gold was trading lower by 0.34% at $3,177.70, Silver was down 0.64% to $32.230, and Copper fell 0.53% to $4.6263.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were down 0.31%, S&amp;P 500 futures declined 0.49%, and Nasdaq 100 futures fell 0.67%.
Forex at 06:00 AM ET
The U.S. Dollar Index declined 0.28% to 100.79, USD/JPY was down 0.55% to 145.87, and USD/AUD rose 0.22% to 1.5589.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips; Dollar Slides Amid Fed Uncertainty - Global Markets Today While US Slept

Leveraging Infosys' global expertise in digital transformation, the collaboration will modernize the bank's IT landscape, enhance customer experience, and optimize operational efficiency
BENGALURU, India, May 15, 2025 /PRNewswire/ -- <a href="https://www.infosys.com/">Infosys</a> (NSE: INFY) (BSE: INFY) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>), a global leader in next-generation digital services and consulting, today announced an expansion of its strategic collaboration with <a href="https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dnb.no%2Fen&amp;data=05%7C02%7Cmelvin.alex%40infosys.com%7C089ecf784317441cb58e08dd913d0d2f%7C63ce7d592f3e42cda8ccbe764cff5eb6%7C0%7C0%7C638826413679085166%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=8Ef%2Bx7Ufu1W1v3Q30pXzVte%2Fjtq7Hv7VGRB2%2BlsP0T4%3D&amp;reserved=0">DNB Bank ASA</a>&nbsp;(DNB), Norway's largest bank, to accelerate the bank's digital transformation. The collaboration will leverage&nbsp;Infosys' services, solutions, and platforms, including the <a href="https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.finacle.com%2F&amp;data=05%7C02%7Cmelvin.alex%40infosys.com%7C089ecf784317441cb58e08dd913d0d2f%7C63ce7d592f3e42cda8ccbe764cff5eb6%7C0%7C0%7C638826413679113286%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=nP9hsDzNnfUwZ9Fb%2FvMw2TL1VF98KIzXBlr%2BtifZ%2Bvk%3D&amp;reserved=0">Infosys Finacle</a> platform to accelerate their IT modernization journey, improve resilience, and deliver enhanced customer experience.

INFY

Infosys Expands Strategic Collaboration With DNB Bank To Accelerate Bank's Digital Transformation

Keyera (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KEY#TSX">KEY</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.52 by 9.62 percent. This is a 83.87 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $1.76 billion which missed the analyst consensus estimate of $1.78 billion by 1.12 percent. This is a 15.71 percent increase over sales of $1.52 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

TSX:KEY

Keyera Q1 EPS $0.57 Beats $0.52 Estimate, Sales $1.76B Miss $1.78B Estimate

Needham analyst Ryan Koontz maintains Radcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDCM#NASDAQ">RDCM</a>) with a Buy and raises the price target from $17 to $18.

RDCM

Needham Maintains Buy on Radcom, Raises Price Target to $18

BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported $3.23 million in sales this quarter. This is a 1.28 percent increase over sales of $3.19 million the same period last year.

BTBD

BT Brands Q1 EPS $(0.05) Up From $(0.07) YoY, Sales $3.23M Up From $3.19M YoY

The quarterly cash dividend amount of $0.18 per share will be paid on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.

Dividends

Advanced Drainage Systems Raises Annual Dividend By 13% To $0.72 Per Share; Sets $0.18 Quarterly Payout For June 16

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $29 price target.

Reiteration

CELC

Needham Reiterates Buy on Celcuity, Maintains $29 Price Target

Citigroup analyst John Yu initiates coverage on Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy rating and announces Price Target of $11.

WBTN

Citigroup Initiates Coverage On Webtoon Entertainment with Buy Rating, Announces Price Target of $11

GPUS

Hyperscale Data Plans To Resume Bitcoin Mining Operations At One Of Its Two Montana Sites On Or Around June 10, 2025

Quarterhill (TSX:<a class="ticker" href="https://www.benzinga.com/stock/QTRH#TSX">QTRH</a>) reported quarterly losses of $(0.07) per share. This is a 75 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $33.89 million in sales this quarter. This is a 2.89 percent decrease over sales of $34.90 million the same period last year.

TSX:QTRH

Quarterhill Q1 EPS $(0.07) Down From $(0.04) YoY, Sales $33.89M Down From $34.90M YoY

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $88.5 price target.

ROKU

Needham Reiterates Buy on Roku, Maintains $88.5 Price Target

Fiscal Year 2026 Outlook
Based on current visibility, backlog of existing orders and business trends, the Company issued the following targets for fiscal 2026. Net sales are expected to be in the range of $2.825 billion to $2.975 billion. Adjusted EBITDA is expected to be in the range of $850 million to $910 million. Capital expenditures are expected to be approximately $275 million.

Guidance

Advanced Drainage Systems Sees FY2026 Sales $2.825B-$2.975B Vs. $3.07B Est

NACCO Industries&#xAE; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) announced today that its Board of Directors declared a regular quarterly cash dividend of 25.25 cents per share, which represents an 11% increase compared to the prior quarterly dividend rate of 22.75 cents per share. The dividend is payable on both the Class A and Class B Common Stock, and will be paid June 16, 2025 to stockholders of record at the close of business on May 30, 2025. The new dividend is equal to an annual rate of $1.01 per share, up 10 cents from the prior annual rate of $0.91 per share. This represents NACCO's seventh consecutive annual dividend increase since the dividend was reset following the spin-off of Hamilton Beach Brands Holding Company in September 2017. NACCO and its predecessor companies have paid quarterly cash dividends to stockholders since 1956.

NACCO Industries Raises Quarterly Cash Dividend 11% From $0.23 To $0.25 Per Share

JP Morgan analyst Samik Chatterjee downgrades Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) from Overweight to Neutral.

Comments

Bioventus

Bioventus (BVS) Options

Bioventus (NASDAQ:BVS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL